Rain Oncology Inc
Change company Symbol lookup
Select an option...
RAIN Rain Oncology Inc
ACST Acasti Pharma Inc
STBX Starbox Group Holdings Ltd
ANCFX American Funds Fundamental Investors® Class A
DFS Discover Financial Services
EJH E-Home Household Service Holdings Ltd
PYXS Pyxis Oncology Inc
FLGC Flora Growth Corp
BAOS Baosheng Media Group Holdings Ltd
CETY Clean Energy Technologies Inc
Go

Rain Oncology Inc., formerly Rain Therapeutics Inc., is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. The Company’s product candidates include milademetan and RAD52. Its milademetan is an oral small molecule, an inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, loss of an MDM2 regulator, or other mechanisms. RAD52 is focused on the DNA Damage Response (DDR) pathway. RAD52 represents a strategy for patients that may exhibit homologous recombination deficiencies (HRD+), or a loss of function, of several pathway constituents, including BRCA1/2, PALB2, or several others in tumor types frequently characterized by these deficiencies.

Price: Delayed
$8.49

Day's Change: -0.145 (-1.68%)

Bid: --

Ask: --

B/A Size: --

Day's High: 8.74

Day's Low: 8.31

Volume (Light) Today's volume of 81,074 shares is on pace to be much lighter than RAIN's 10-day average volume of 267,987 shares.: 81,074

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.